Drawing for PERIMAG

USPTO serial 79192642

PERIMAG

Reviewed by CopyMark Law Group

Reg. 5258234Status 707Renewal
Filing date
Status date
Registration date
Aug 8, 2017
Examiner
SHANOSKI, JOANNA MARIE
Law office
—

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with PERIMAG?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Martin R. Geissler

Martin R. Geissler Muncy, Geissler, Olds & Lowe, P.C.125 S. Royal StreetAlexandria, VA 22314UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical products for commercial and scientific purposes, namely, nanoparticles and microparticles composed primarily of magnetizable material for use as contrast agents in Magnetic Resonance Imaging and Magnetic Particle Imaging for use in commercial and scientific applications; nanoparticles and microparticles composed primarily of magnetizable material for use in homing and tracking of stem cells in regenerative medicine and for hyperthermia applications for use in commercial and scientific applications; chemical products for commercial and scientific purposes, namely, nanoparticles and microparticles composed of both magnetizable material and organic polymers for use in biomedical research; chemical products for commercial and scientific purposes, namely, nanoparticles and microparticles that are equipped on their surface with functional properties, namely, antibody-coated, radionuclide doped, and fluorescently labeled for pharmaceutical research, cancer diagnostics and treatment research or stem cell treatment researchACTIVE—
005[Diagnostic preparations for medical purposes, namely, magnetizeable nano and micro particles for use in carrier-supported immunologice medical test analysis, in biochemistry or clinical chemistry, in transport- and separation-methods for medical testing for the presence of nucleic acids, tumor markers or other disease-relevant biomolecules, and in imaging tests; therapeutic pharmaceuticals, namely, magnetizeable nano and micro particles for the treatment of cancer, auto-immune diseases, or cardiovascular diseases; pharmaceutical and veterinary products, namely, magnetizeable nano and micro particles for use in targeted drug delivery and physical therapy methods, such as magnetic field-induced hyperthermia]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 8, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Apr 2, 2026RNWLINTERNATIONAL REGISTRATION RENEWED—
Apr 12, 2025INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Feb 18, 2025INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Feb 13, 2025XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Feb 13, 2025XXCRGENERIC MADRID TRANSACTION CREATED—
Dec 18, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 17, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 18, 2024NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Apr 17, 202471.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
Apr 9, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 31, 2023ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 8, 2023ES71TEAS SECTION 71 RECEIVED—
Aug 8, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Dec 15, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Nov 27, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Nov 27, 2017FIMPFINAL DISPOSITION PROCESSED—
Nov 8, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 8, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 23, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 23, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 3, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 14, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 13, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 12, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 12, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 11, 2016RFNTREFUSAL PROCESSED BY IB—
Oct 23, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 22, 2016RFRRREFUSAL PROCESSED BY MPU—
Oct 11, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 8, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 7, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 5, 2016DOCKASSIGNED TO EXAMINER—
Oct 5, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 1, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance